Kornimate/medical-research-clean huggingface dataset:
oxygenation efficacy of "intrinseque health" non-rebreathing mask ("ihnrm")

Conditions: Respiratory Disease; Respiratory Distress Syndrome; Respiratory Failure

Summary: based on early bench-testing data and subsequent clinical case studies in the u.s., "intrinseque health" non-rebreathing mask (ihnrm) has delivered virtual elimination of air entrainment and preferential delivery of all available oxygen first into the alveolar spaces by sequential opening of valves in its controller manifold, even at oxygen flow as low as 10 lpm, patient can attain high alveolar oxygen concentration of 75% or more-far higher than attainable with face mask or nasal cannula. numerous intubated patients emerging from the operating room require intensive critical care specialist supervision in order to transition to the regular care. this would enable higher patient turnover and more efficient utilization of hospital resources, if patient can be transited to the regular care earlier by using a device that supports high oxygenation. this will enable a faster, safe and smooth extubation in critical care, and earlier discharge from intensive care ward. this study is anticipated to take only around 2.5 hour per patient to complete. patients meeting the inclusion and exclusion criteria of this study are placed on ihnrm and monitored until steady state of spo2 of 95% or higher on 7-10 lpm has been maintained for at least 2 hours, when they can be discharged from the post-anesthesia care unit (pacu) to the regular care ward. the study is the parallel design study. 60 patients will be randomly selected to use the ihnrm, and 30 subjects will be placed on hfnc. blood oxygen concentration (spo2), respiratory rate, end tidal co2 concentration (etco2), and vital sign will be recorded in the study. the endpoint of the study is to compare the effect after using between "ihnrm" and hfnc.


Eligibility criteria:
inclusion criteria: 1. any hospitalized patient in moderate to moderately severe respiratory distress and able to breathe spontaneously, and with spo2 (oxygen saturation by pulse oximetry) reading of: (i) 90% or less on room air, or (ii) \<95% in spite of oxygen supplementation on another form of oxygen supplementation. 2. has minimum ideal body wt. of at least ≥15 kg., and at least 3 years old. 3. self/guardian-able to consent to study participation and monitoring. exclusion criteria: patient with any of the following present will be excluded: 1. agitated or confused or somnolent mental state. 2. any impairment of gag reflex. 3. multi-organ failure that may decompensate rapidly, with or without hypoperfusion secondary to cardiogenic, hypovolemic, or septic shock. 4. acute mi, pulmonary embolism, pneumothorax or stroke 5. inability to pull mask off (or to side of) face in emergency. 6. icp (intracranial pressure) \> 15mmhg. if icp unknown but clinically may have elevated icp (such as head trauma or cns tumor), patient should be excluded.

Keywords: spo2、extubation、etco2
maintenance chemotherapy in high-metastatic risk nasopharyngeal carcinoma patients of n3 stage

Conditions: Nasopharyngeal Carcinoma

Summary: up to now, imrt has largely improved the local control of locally advanced nasopharyngeal carcinoma (npc), leaves the distant metastasis as the main treatment failure modality of patients with bulky lymph nodes (especially n3 stage). although concurrent chemoradiotherapy (ccrt) continues to stand as the standard treatment of these patients, the role of adjuvant chemotherapy remains controversial due to its relatively severe toxicities and inferior compliance. however, our retrospective study of 2d-rt and imrt era had proved adjuvant chemotherapy played key role in n3 npc patients in terms of reducing distant metastasis and improving overall survival. maintenance chemotherapy of gemicitabine single drug is promising with adequate efficacy and moderate toxicities. so we aim to conduct "a phase iii randomized trial of maintenance chemotherapy in high-metastatic risk nasopharyngeal carcinoma patients of n3 stage" to evaluate the effectiveness and compliance of gemicitabine as maintenance chemotherapy in n3 nasopharyngeal carcinoma.

we aim to conduct "a phase iii randomized trial of maintenance chemotherapy in high-metastatic risk nasopharyngeal carcinoma patients of n3 stage" to evaluate the effectiveness and compliance of gemicitabine as maintenance chemotherapy in n3 nasopharyngeal carcinoma.

Eligibility criteria:
inclusion criteria: * ajcc/uicc 8th edition n3 nasopharyngeal carcinoma * pathology: who ii/ii * no prior anti-tumor treatment * age 18-60 * kps≥70 * adequate blood supply * informed consent obtained exclusion criteria: * pathology: who i * pregnant * combined with other malignant tumor
a study to explore treatment regimens and clinical outcomes of the nsclc patients with different dirver genes

Conditions: Non-small Cell Lung Cancer

Summary: a single-center, non-interventional prospective observational study in the nsclc patients with different driver genes

the trial was designed as a single-center non-interventional prospective observational study to explore clinical treatments of the nsclc patients with different driver genes, the impact factors of patient survivals, and the relevance of gene types, clinical treatments, and distribution of gene types. the follow-up visits, interactions between the investigators and patients, patient questionnaires/quality of life, and other patient information will be uploaded via mobile app, and webchat every three months.

Eligibility criteria:
inclusion criteria: * the patients with lung cancer who were performed with next-generation sequencing (ngs) technology from 2015 to 2017; * the patients who were at least 18 years; * the pathologically diagnosed patients with non-small cell lung cancer (nsclc) exclusion criteria: -none

Keywords: non-small cell lung cancer, gene mutations
massage therapy for hiv-positive people : effects on anxiety, depression, hyperventilation and quality of life

Conditions: HIV-positive Diagnosis

Summary: massage therapy during 1 month and evaluation of depression, hyperventilation, anxiety and quality of life


Eligibility criteria:
inclusion criteria: * hiv-positive diagnosis exclusion criteria: * musculoskeletal disorders
respiratory side effects of busulfan high dose chemotherapy in a pediatric population

Conditions: Signs and Symptoms, Respiratory

Summary: recently, several conditioning regimens did not include total body irradiation (tbi) anymore, especially in the case of young children due to cognitive sequelae and late effects on growth and height. thus, such effective chemotherapy conditioning regimens were developed to avoid these complications. busulfan is one of the major drugs used in these treatments, but, is also administered in high dose chemotherapy followed by autograft. in both situations, long term pulmonary side effects were diagnosed in a few cases. even if the occurrence is not very frequent, the clinical management is a real challenge regarding the reduced quality of life and life expectancy of these patients. up to now, no correlation was done between respiratory sequelae and busulfan pharmacokinetics. hence, in the investigators' pediatric onco-hematological unit, a prospective study will begin and last three years to assess the respiratory side effects due to busulfan and their potential links with individual drug pharmacokinetic measures. these results will be compared to patients treated with tbi during the same period of time.


Eligibility criteria:
inclusion criteria: * patients above 3 years old treated by busulfan or tbi in their conditioning regimens before allograft or busulfan in high dose chemotherapeutic regimens followed by autograft will be included after parents informed assent.

Keywords: busulfan pharmacokinetic respiratory function assessment busulfan pharmacokinetic and respiratory function tests
ecg optimization of crt: evaluation of mid-term response

Conditions: Heart Failure

Summary: new simpler methods to optimize cardiac resynchronization therapy (crt) are being evaluated, such as the use of the electrocardiogram. in this prospective, double-blind, study, the investigators will evaluate: primary endpoint: to compare the clinical response to crt in patients with the programming optimized by qrs versus the nominal suggested by the device. secondary endpoints: 1. to compare cardiac remodeling in patients with the programming optimized by qrs versus the nominal suggested by the device. 2. to evaluate the degree of asynchrony in both groups (nominal versus optimization by qrs) with respect to the intrinsic rhythm. 3. to evaluate the echocardiographic improvement in left ventricular (lv) filling in both groups. 4. to evaluate the differences in the optimal atrioventricular (av) delay with atrial sensing or atrial pacing. for that, 180 patients with an indication for crt will be randomized to nominal programming of the device or optimization by the electrocardiogram for a narrower qrs. a clinical and echocardiographic evaluation will be done at baseline, 6 and 12 months.


Eligibility criteria:
inclusion criteria: patients with standard indication of cardiac resynchronization * ejection fraction ≤35%. * qrs duration ≥120 ms. * new york heart association functional class 2-4.. * left ventricular diameter ≥55 mm. * optimal medical treatment. exclusion criteria: * patient refusal. * cardiopathy with a reversible cause. * prevision of heart transplantation. * atrial fibrillation. * complete av block. * av delay \>250 ms. * right bundle branch block. * severe peripheral vascular disease. * other diseases with \< 1 year life expectancy

Keywords: cardiac resynchronization therapy
treatment of patients with teduglutide (glp-2) for gvhd and analysis of paneth cells of gvhd patients

Conditions: Graft Versus Host Disease

Summary: in this study the investigators evaluate the outcomes of six steroid-refractory gvhd patients with gastrointestinal signs of gvhd that were treated with teduglutide.

preliminary studies have showed that glucagon-like peptide 2 (glp-2) has regenerative and protective effects on the gastrointestinal tract after bowel injury. it induces positive effects in the gi tract like nutrient uptake, mucosal growth, protection from inflammation, etc. one of the target organs from gvhd is the gi tract, and since patients suffering from gi-gvhd experience intestinal disorders like loss of mucosal epithelial integrity, diarrhea accompanied by strong abdominal pain that can lead to food inanition, the investigators therefore aimed to examine the outcome of patients suffering from sr-gi-gvhd that are treated with the glp-2 analogue, teduglutide. the investigators will determine the outcome of each patient by monitoring the gastrointestinal signs like diarrhea frequency, intestinal absorption measured by serum-albumin concentrations and gi histology, specifically the number of paneth cells before and during teduglutide treatment.

Eligibility criteria:
inclusion criteria: * patients with signs of acute sr-gi-gvhd * age ≥ 18 years * peripheral blood and stool samples available before and during treatment * written informed consent * ability to understand the nature of the study and the study related procedures and to comply with them exclusion criteria: * age ≤ 18 years * lack of informed consent
schizophrenic patients in integrated care

Conditions: Schizophrenia; Schizoaffective Disorder; Schizophreniform Disorder

Summary: the purpose of the study is to investigate the well-being of schizophrenic patients treated with quetiapine xr combined with participation in the integrated care program compared to a treatment with quetiapine xr alone over a period of 18 month


Eligibility criteria:
inclusion criteria: * patients with baseline swn-k \<=70 * provision of signed informed consent * out-patients with schizophrenia, schizophreniform disorder or schizoaffective disorder, severe postpartum depressive disorders with psychotic symptoms and a minimum ham-d cut off score of 20 points exclusion criteria: * evidence of a clinical relevant disease, eg renal or hepatic impairment, significant coronary heart disease, hepatitis b or c, aids * patients with known cardiovascular disease or other condition predisposing to hypotension or family history of qt prolongation * patients who pose an imminent risk of suicide or danger to self or others

Keywords: schizophrenia integrated care quetiapine
postoperative new-onset atrial fibrillation in cardiac surgery: decs-pnaf project

Conditions: Atrial Fibrillation; Cardiac Surgery

Summary: the dexamethasone for cardiac surgery - postoperative new-onset atrial fibrillation (decs-pnaf) project described in this protocol aims to elucidate how corticosteroids protect cardiac surgical patients from postoperative new-onset atrial fibrillation (pnaf). patients will be randomized to receive either a single high dose of dexamethasone or a placebo. continuous ecg-monitoring, echocardiography and biochemical and genomic analyses will be used to investigate the mechanisms responsible for the known protective effect of corticosteroids in the development of pnaf.

postoperative new-onset atrial fibrillation (pnaf) is a common complication after cardiac surgery, affecting up to 60% of patients. pnaf has been associated with a higher incidence of adverse postoperative outcomes including long-term mortality, and leads to an increased use of resources and higher social costs. many studies have investigated potential determinants of pnaf. established determinants can grossly be divided into inflammatory factors, cardiac functional (echographic) parameters, cardiac electrophysiologic properties and other (demographic) risk factors. also, a substantial number of studies have investigated pharmacological prophylactic strategies. in these studies, the highest effectiveness has been shown for strategies involving either betablockers, statins and, more recently, corticosteroids. the dexamethasone for cardiac surgery - postoperative new-onset atrial fibrillation (decs-pnaf) project described in this protocol aims to elucidate how corticosteroids protect cardiac surgical patients from pnaf. the modulating effect of intraoperative prophylactic high-dose dexamethasone administration on the categories of perioperative determinants of pnaf mentioned above will be studied in 164 coronary artery bypass grafting surgery patients. for this, multiple perioperative assessments will be performed using, for example, repeated biochemical assessment of inflammation, genomic analysis of (mainly inflammatory) single nucleotide polymorphisms, continuous electrocardiographic (holter) monitoring and transesophageal echocardiography. the decs-pnaf project is one of the first prospective studies to combine a detailed assessment of multiple categories of pnaf determinants. moreover, it is unique in studying the effect of prophylactic corticosteroid administration on every one of these determinants.

Eligibility criteria:
inclusion criteria: * on-pump coronary artery bypass graft (cabg) exclusion criteria: * age \< 18 years * preexisting cardiac rhythm disturbances

Keywords: atrial fibrillation cardiac surgery cardiopulmonary bypass new-onset
usability of virtual reality in subjects with mild cognitive impairment or alzheimer's disease

Conditions: MCI; Alzheimer's Disease

Summary: cognitive and memory problems characterize alzheimer's disease (ad). along with these disorders, psychological and behavioral symptoms (also known as neuropsychiatric symptoms) , as well as pathophysiological processes are frequently found and involved significantly in maintaining autonomy, prognosis and treatment of the disease. apathy or disorder motivation is the most common disorder behavior and early stages of cognitive impairment. apathy is particularly associated with cognitive difficulties such as attention deficit disorder - concentration. in terms of prevention as term care , there is now a broad consensus that interventions on cognition and behavior must not be limited to pharmacological treatment but should also promote non-drug approaches. interest in video games (serious games and serious games) as intervention support rehabilitation is growing. similarly, the virtual reality (vr) and the new information technologies and communications offer significant opportunities in terms of rehabilitation and therapeutic assistance. this protocol is part of a european project to propose techniques for improving the treatment of people at risk of social exclusion ( verve project ) aims . a first experiment conducted in 2013 showed the acceptability of virtual reality (vr) in healthy elderly subjects. in a second step , it is important to validate the feasibility of using the rv or in frail subjects with mild cognitive impairment or alzheimer's disease in mild to moderate in a clinical environment. this is a biomedical , randomized given to a group of patients with mild cognitive impairment or alzheimer's disease \& diseases associated with mild to moderate.


Eligibility criteria:
inclusion criteria: * male or female age ≥ 60 years. * introducing either: * mci diagnosis (icd-10) * diagnosis of alzheimer's disease or mixed mild to moderate (icd 10). * subject undisturbed locomotion requiring the use of a walking aid. * score at the mini mental test (mmse) between 16 and 28. exclusion criteria: * presence of psychiatric disorders * presence of eye diseases causing blurred vision can not be corrected with lenses or glasses. * presence of auditory pathologies causing a significant decrease in hearing unaided. * high sensitivity to motion sickness. * migraine disease. * subject epileptic. * subject vulnerable

Keywords: virtual reality mild cognitive impairment alzheimer's disease
effect of glucose on ocular blood flow

Conditions: Coronary Vasospasm

Summary: the primary objective is to assess the effect of glucose on retinal vascular diameter in otherwise healthy vasospastic subjects compared to non-vasospastic controls. the secondary objective is to compare the effect of glucose also on choroidal blood flow in otherwise healthy vasospastic subjects with non-vasospastic controls.

it is known that a glucose load can induce an increase in ocular blood flow. acute hyperglycemia increases retinal vessel diameters in animals and humans. the purpose of this study is to compare the effect of glucose on the ocular blood flow in vasospastics and nonvasospastics. body core temperature depends on basal metabolism. peripheral vasoconstriction is a physiological way to preserve core temperature of the body. the etiology of primary vasospastic syndrome is unknown and potentially represents simply a reaction to a defective metabolism. based on this hypothesis, vasospastics are expected to show a different vascular reaction to glucose. on both study days, after an overnight fast, the subjects will be seated for 30 minutes in the lab and local tropicamide will be applied for pupil dilatation. after stabilisation of blood pressure retinal vessel diameter and choroidal blood flow will be assessed. baseline blood glucose levels will be measured. afterwards study substance (75 gram of glucose or aspartate) will be applied in 3 dl of water. one and a half hour later, the vascular measurements will be repeated. ath the end of hemodynamic assessments, blood sugar level will be measured again.

Eligibility criteria:
inclusion criteria: * no history of the following problems: ocular or systemic disease; chronic or current systemic or topical medication; or of drug or alcohol abuse * normal blood pressure (100-140 / 60-90 mmhg) * best corrected visual acuity above 20/25 in both eyes * no pathological findings upon a slit-lamp examination and indirect fundoscopy * ametropia within -3 to +3 diopters of spherical equivalent * less than 1 diopter astigmatism * iop \< 20 mmhg in both eyes * subjects will be classified as vasospastic if they relate a clear history of frequent cold hands (answering yes to the questions: "do you have always cold hands, even during summer time?" and "do other people tell you that you have cold hands?") and as normals if they deny such a history * vasospastic propensity will also be assessed by capillaroscopy exclusion criteria: * subjects describing "sometimes cold hands" * if the test substance cannot be ingested * not obtainable ocular blood flow measurements * abnormally high levels of glucose at any point in time

Keywords: glucose vasospasm rva ldf vasospastic subjects non-vasospastic subjects
effect of chitosan-n-acetylcysteine on iol-power prior to cataract surgery

Conditions: Eye Diseases

Summary: aim of this study is to evaluate the effect of treatment with lacrimera® on calculated iol power prior to cataract surgery and on the stability of ocular surface parameters compared to preservative-free, hyaluronic-acid containing eyedrops (hylo-vision® sine).

the present study seeks to investigate the effect of treatment with lacrimera® on the calculated iol power prior to cataract surgery and on the stability of ocular surface parameters compared to preservative-free, hyaluronic-acid containing eyedrops (hylo-vision® sine).

Eligibility criteria:
inclusion criteria: * age older than 18 years * corneal staining (marked to severe; nei grading scale \>=10) exclusion criteria: * usage of eye drops other than lubricants (e.g. antibiotics, steroids, cyclosporin-a) * usage of systemic antibiotic therapy 7 * any pathology of the ocular surface except dry eye disease (e.g. corneal scarring, cornea ectasia) * ocular surgery within prior 3 months * preceding refractive surgery (e.g. lasik) * ocular injury within prior 3 months * ocular herpes of eye or eyelid within prior 3 months * active ocular infection * active ocular inflammation or history of chronic, recurrent ocular inflammation within prior 3 months * eyelid abnormalities that affect lid function * ocular surface abnormality that may compromise corneal integrity * pregnancy and nursing women (in women of childbearing age a pregnancy test will be performed before inclusion into the study)